Defining adenoma detection rate benchmarks in average-risk male veterans - 19/12/18
Abstract |
Background and Aims |
Veterans have higher prevalence of colorectal neoplasia than non-veterans; however, it is not known whether specific Veterans Affairs (VA) adenoma detection rate (ADR) benchmarks are required. We compared ADRs of a group of endoscopists for colonoscopies performed at a VA center with their ADRs at a non-VA academic medical center.
Methods |
This was a retrospective review of screening colonoscopies performed by endoscopists who practice at the Indianapolis VA and Indiana University (IU). Patients were average-risk men aged 50 years or older. ADR, proximal ADR, advanced ADR, and adenomas per colonoscopy were compared between IU and the VA groups.
Results |
Six endoscopists performed screening colonoscopies at both locations during the study period (470 at IU vs 608 at the VA). The overall ADR was not significantly different between IU and the VA (58% vs 61%; P = .21). Advanced neoplasia detection rate (13% vs 17%; P = .46), proximal ADR (46% vs 47%; P = .31), and adenomas per colonoscopy (1.59 vs 1.84; P = .24) were not significantly different. There were no significant differences in cecal intubation rate (100% vs 99%; P = .13) or withdrawal time (10.9 vs 11.1 min; P = .28). In regression analysis, there was significant correlation between the attending-specific ADRs at IU and the VA (P = .041, r2 = 0.69).
Conclusions |
In this study of average-risk men undergoing screening colonoscopies by the same group of endoscopists, the ADRs of VA and non-VA colonoscopies were not significantly different. This suggests that a VA-specific ADR target is not required for endoscopists with high ADRs.
Le texte complet de cet article est disponible en PDF.Abbreviations : ADR, BMI, CRC, FDR, GEE, IU, NSAID, VA
Plan
| DISCLOSURE: Supported in part by the Cordelia Collins Research Fund (C. Kahi). D. Rex, consultant for Aires Pharmaceuticals, Cosmo Pharmaceuticals, Boston Scientific, Olympus Corp, and Braintree; Research support from Boston Scientific, Sebela, Medtronic, EndoAid Ltd, Olympus Corp, Braintree, and Medivators. All other authors disclosed no financial relationships relevant to this publication. |
|
| If you would like to chat with an author of this article, you may contact Dr Kahi at ckahi2@iu.edu. |
Vol 89 - N° 1
P. 137-143 - janvier 2019 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?
